Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments

Next Previous
Trial Profile

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LU AG09222 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors Lundbeck A/S

Most Recent Events

  • 14 Sep 2023 According to H. Lundbeck A/S media release, the company announced the data from this study at the International Headache Congress (IHC) 2023 in Seoul, Korea.
  • 14 Sep 2023 Primary endpoint (Change From Baseline in the Number of Monthly Migraine Days (MMDs) at Month 1 (Weeks 1-4)) has been met.
  • 14 Sep 2023 Results published in H. Lundbeck A/S media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top